For AI to be transformative in the pharmaceutical industry, it must be designed with a security-first approach. This means ...

The transition from writing to programming regulatory submissions represents one of the most significant efficiency ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

The CGM is based on magnetohydrodynamic (MHD) technology, which non-invasively samples interstitial fluid, the body fluid ...

Finding a conversation about AI at a conference like BIO 2025 is easy. But making those conversations meaningful and asking ...

According to the government, the passport will eliminate multiple compliance assessments, reducing duplication across the ...

The One Big Beautiful Bill (BBB), which passed (PDF) by a 51-50 vote with Vice President JD Vance casting the tie-breaker, ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

The 7th Exosome-Based Therapeutics Development Summit with never-before-seen data, covering the end-to-end from discovery ...

Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...